登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688277 证券简称：天智航 公告编号：2025-042 北京天智航医疗科技股份有限公司 2023年限制性股票激励计划首次及预留授予部分 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为3,323,445股（其中首次授予部 分2,602,855股，预留授予部分720,590股）。 本次股票上市流通总数为3,323,445股。 ● 本次股票上市流通日期为2025年10月24日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务规则的规定， 北京天智航医疗科技股份有限公司（以下简称"本公司"、"公司"）于近日收到中国证券登记结算有限责 任公司上海分公司出具的《证券变更登记证明》，公司完成了2023年限制性股票激励计划首次及预留授 予部分第二个归属期的股份登记工作。现将有关情况公告如下： 5、2023年5月12日，公司于上 ...

Core Viewpoint - Tianzhihang announced the results of the second vesting period for its 2023 restricted stock incentive plan, indicating a focus on employee motivation and retention through equity incentives [1] Group 1 - The type of stock listed is equity incentive shares [1] - The total number of shares available for circulation is 3,323,445 shares [1] - The stock subscription method is offline [1] Group 2 - The listing date for the stock circulation is set for October 24, 2025 [1]

证券代码：688277 证券简称：天智航 公告编号：2025-042 北京天智航医疗科技股份有限公司 2023 年限制性股票激励计划首次及预留授予部分 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，北京天智航医疗科技股份有限公司（以下简称"本公 司"、"公司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的 《证券变更登记证明》，公司完成了 2023 年限制性股票激励计划首次及预留授予 部分第二个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 4 月 25 日，公司召开第五届董事会第二十一次会议，审议通过了 《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司 <2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授 权董事会办理公司 2023 年限制性股票激励 ...

Core Viewpoint - Tianzhihang (688277) is actively pursuing an overseas expansion strategy, showcasing its technological innovations and product offerings at international exhibitions, and has achieved CE certification for its orthopedic surgical navigation system, laying the groundwork for entering overseas markets [1][3]. Group 1: Company Performance - As of October 17, 2025, Tianzhihang's stock closed at 17.53 yuan, down 2.77% from the previous week [1]. - The company has maintained the largest market share in the domestic orthopedic robot market, with a significant increase in bidding activity, showing over 50% year-on-year growth in orthopedic robot tenders [1][3]. Group 2: Technological Advancements - Since 2006, the company has been a pioneer in remote orthopedic robotic surgery, completing over 1,000 remote surgeries across 24 provinces and municipalities, establishing 5G remote surgery as a standard practice [2][3]. - The company has received approval for robotic-assisted orthopedic surgery in over 20 provinces and cities, with Beijing including it in its medical insurance payment directory [2][3]. Group 3: Corporate Governance - The second extraordinary general meeting of shareholders was held on October 16, 2025, with 203 shareholders present, representing 36.03% of the voting shares [3][4]. - The meeting approved the increase of the estimated amount for daily related transactions and the re-election of a non-independent director, with no proposals being rejected [3][4].

证券代码：688277 证券简称：天智航 公告编号：2025-041 北京天智航医疗科技股份有限公司 2025年第二次临时股东大会决议公告 | 1、出席会议的股东和代理人人数 | 203 | | --- | --- | | 普通股股东人数 | 203 | | 2、出席会议的股东所持有的表决权数量 | 163,099,779 | | 普通股股东所持有表决权数量 | 163,099,779 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 36.0307 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 36.0307 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 16 日 （二） 股东大会召开的地点：北京市海淀区建枫路（南延）中关村西三旗金隅 科技园 8 号院 2 号楼北京 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 北京市康达律师事务所 关于北京天智航医疗科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致：天智航医疗科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受北京天智航医疗科技股份 有限公司（以下简称"公司"）的委托，就公司 2025 年第二次临时股东大会 （以下简称"本次会议"）的相关事宜出具《北京市康达律师事务所关于北京天 智航医疗科技股份有限公司 2025 年第二次临时股东大会的法律意见书》（以 下简称本"《法律意见书》"）。本所 ...

Core Viewpoint - Tianzhihang's stock price has experienced fluctuations, with a year-to-date increase of 71.17%, but a recent decline in the last five trading days by 6.91% [1] Group 1: Stock Performance - As of October 15, Tianzhihang's stock price was 17.10 CNY per share, with a market capitalization of 7.741 billion CNY [1] - The stock has seen a trading volume of 11.2079 million CNY, with a turnover rate of 0.14% [1] - Year-to-date, the stock has risen by 71.17%, but has declined by 6.91% over the last five trading days and 3.82% over the last twenty days [1] Group 2: Financial Metrics - For the first half of 2025, Tianzhihang reported revenue of 125 million CNY, representing a year-on-year growth of 114.89% [2] - The company recorded a net profit attributable to shareholders of -57.5482 million CNY, a decrease of 23.80% year-on-year [2] Group 3: Business Overview - Tianzhihang specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with main business revenue composition: 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and equipment [2]

Core Insights - The article discusses the shift in the surgical robot market in China from being dominated by foreign brands to a more competitive landscape with domestic companies making significant advancements in technology and clinical applications [1][2][3]. Market Overview - The global surgical robot market is projected to grow from approximately $18.074 billion in 2023 to $20.4 billion in 2024, with a compound annual growth rate (CAGR) of 23.75% over the next five years [1]. - The Chinese surgical robot market is expected to reach approximately 9.59 billion yuan in 2024, with a CAGR of 34.5%, and is projected to grow to 11.03 billion yuan by 2025 [2]. Competitive Landscape - Currently, the domestic surgical robot market is characterized by a "foreign dominance, domestic pursuit" trend, with the top eight brands in sales being evenly split between imported and domestic brands [3]. - As of 2025, the market share of domestic brands in the surgical robot sector is approximately 29.82%, while imported brands hold 70.18% [4]. Brand Performance - Intuitive Surgical's Da Vinci system maintains a leading position in the laparoscopic surgical robot market with a market share of 53.8% as of Q2 2025, generating revenue of $2.44 billion (approximately 17.5 billion yuan) with a year-on-year growth of 21.4% [5][7]. - Domestic brands are gaining traction, with a significant increase in the number of Da Vinci robots installed in China, rising from a 42% market share to 62% [7]. Growth of Domestic Brands - From January to May 2025, the number of domestic surgical robots awarded contracts increased by 82.9%, indicating a strong competitive push against foreign brands [9]. - The domestic market for laparoscopic surgical robots has seen a domesticization rate of approximately 44.4% in Q1 2025, meaning nearly 4.5 out of every 10 new installations are from domestic brands [9]. Pricing Dynamics - Domestic surgical robots are priced significantly lower than their foreign counterparts, with prices for domestic laparoscopic robots typically ranging from 12 million to 18 million yuan, compared to the Da Vinci system's price range of 14.99 million to 24.92 million yuan [13][14]. - The price competition has intensified, with some domestic brands offering robots at prices as low as 5.38 million yuan, while the Da Vinci system averages around 23 million yuan [25]. Challenges and Opportunities - Despite rapid growth, domestic surgical robot manufacturers face challenges such as reliance on imported core components, which account for 70-80% of the total cost [17]. - The technological gap between domestic brands and international leaders like Intuitive Surgical remains significant, with the latter holding over 700 patents that create a strong barrier to entry [20]. Future Directions - To succeed, domestic surgical robot companies must innovate through technology upgrades and business model transformations, such as integrating 5G and AI technologies to enhance operational efficiency and reduce costs [38][40]. - The Chinese government has introduced supportive policies, including insurance coverage for surgical robots, which could facilitate market penetration and adoption [44][45]. Conclusion - The future of domestic surgical robots hinges on achieving technological independence, leveraging AI and 5G, and establishing sustainable business models to transition from merely entering the operating room to securing a stable presence within it [46].

Core Insights - The dominance of Intuitive Surgical's da Vinci surgical robot system in the U.S. market is being challenged by the rise of domestic surgical robot companies in China, leading to a more competitive landscape [1][2] - The market share of domestic laparoscopic surgical robots in China is projected to grow significantly, indicating a shift from foreign dominance to a more balanced competition [4][5] Market Overview - The global surgical robot market is expected to reach approximately $18.074 billion in 2023 and $20.4 billion in 2024, with a compound annual growth rate (CAGR) of 23.75% over the next five years [6] - The Chinese surgical robot market is anticipated to grow to approximately 9.59 billion yuan in 2024, with a CAGR of 34.5%, reaching 11.03 billion yuan by 2025 [8] Competitive Landscape - By the first quarter of 2025, the number of imported and domestic brands in the top eight sales positions in China is expected to be equal, with two out of the top three brands being domestic [9] - Despite the increasing presence of domestic brands, imported brands still hold a significant market share, with 70.18% compared to 29.82% for domestic brands [10] Technological Advancements - Domestic surgical robot companies are making strides in technology, with a notable increase in the number of approved products and market entries [41][42] - The introduction of AI and remote surgical technologies is expected to enhance the capabilities of domestic surgical robots, potentially increasing market penetration [60][63] Financial Performance - Domestic companies like Tianzhihang have reported significant revenue growth, with a 114.89% increase in revenue in the first half of 2025 compared to the previous year [32][33] - However, many domestic companies are still operating at a loss, indicating challenges in achieving sustainable profitability [46][50] Challenges and Opportunities - The reliance on imported core components poses a significant challenge for domestic surgical robot manufacturers, as these components account for 70%-80% of the total cost [35] - The ongoing U.S.-China trade tensions have created opportunities for domestic brands to capture market share by offering more cost-effective alternatives to imported systems [24][26] Policy Support - Recent government policies have begun to support the integration of surgical robots into healthcare systems, with reimbursement rates for surgical robot procedures being established in various provinces [73][74] - The promotion of a "product + service" model by local governments aims to enhance the competitiveness of domestic surgical robot companies [68] Conclusion - The future of domestic surgical robots in China will depend on technological advancements, innovative business models, and effective policy support to transition from merely entering the market to establishing a strong foothold [75]

北京天智航医疗科技股份有限公司 2025年第二次临时股东大会会议资料 北京天智航医疗科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年十月 北京天智航医疗科技股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 2025 | 年第二次临时股东大会会议须知 1 | | --- | --- | | 2025 | 年第二次临时股东大会会议议程 3 | | 议案一：《关于增加 | 年度日常关联交易预计额度的议案》 4 2025 | | | 议案二：《关于补选公司第六届董事会非独立董事的议案》 5 | 北京天智航医疗科技股份有限公司 2025年第二次临时股东大会会议资料 北京天智航医疗科技股份有限公司 2025 年第二次临时股东大会会议须知 各位股东及股东代表： 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》、 中国证监会《上市公司股东会规则》以及《北京天智航医疗科技股份有限公司章 程》《北京天智航医疗科技股份有限公司股东大会议事规则》的相关规定，特制 定 2025 年第二次临时股东大会会议须知： ...